Drug agency to probe safety of Levovir

Published: 2009-04-28 06:59:00

Updated: 2009-04-28 06:59:00

The Korea Food and Drug Administration has recently announced it will examine on May 2 the safety of Levovir (clevudine) that is confirmed to have caused serious myopathy in patients with hepatitis B.

The announcement comes as the US based Pharmasset terminated its phase III clinical trial due...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK